quinazolines has been researched along with Thromboembolism in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bharathan, R; Chuai, Y; Dai, G; Li, Y; Otter, SJ; Rizzuto, I; Stewart, A; Wang, A; Zhang, X | 1 |
| Amarshi, N; Billingsley, A; Nair, BA; Thomas, KS | 1 |
| Bartell, S; Mahajan, S; Tibbles, HE; Uckun, FM; Vassilev, A; Zheng, Y | 1 |
| Petrides, PE | 1 |
| Clausen, NT; Hansen, PB; Hasselbalch, HC; Jensen, BA; Mourits-Andersen, T; Nielsen, OJ; Penninga, E | 1 |
| Hehlmann, R; Lengfelder, E | 1 |
3 review(s) available for quinazolines and Thromboembolism
| Article | Year |
|---|---|
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Bias; Brachytherapy; Combined Modality Therapy; Confidence Intervals; Female; Gastric Fistula; Gastrointestinal Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Fistula; Intestinal Perforation; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Pyridines; Pyrimidines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Thromboembolism; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Young Adult | 2021 |
Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
Topics: Animals; Carcinogens; Clinical Trials as Topic; Drug Therapy, Combination; Heart Diseases; Humans; Hydroxyurea; Interferon Type I; Mutagens; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Recombinant Proteins; Thrombocythemia, Essential; Thromboembolism | 2004 |
[Polycythemia vera: current status of therapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bloodletting; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Leukemia; Middle Aged; Phlebotomy; Pipobroman; Platelet Aggregation Inhibitors; Polycythemia Vera; Prognosis; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Thromboembolism | 2000 |
1 trial(s) available for quinazolines and Thromboembolism
| Article | Year |
|---|---|
Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.
Topics: Adult; Aged; Anemia; Chronic Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Thrombocytosis; Thromboembolism; Treatment Outcome | 2004 |
2 other study(ies) available for quinazolines and Thromboembolism
| Article | Year |
|---|---|
Elevated international normalized ratio associated with concomitant warfarin and erlotinib.
Topics: Adenocarcinoma; Anticoagulants; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; International Normalized Ratio; Lung Neoplasms; Male; Middle Aged; Quinazolines; Thromboembolism; Warfarin | 2010 |
The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Topics: Adenosine Diphosphate; Agammaglobulinaemia Tyrosine Kinase; Amides; Animals; Aspirin; Bleeding Time; Catalytic Domain; Collagen; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fibrinolytic Agents; Humans; Janus Kinase 3; Male; Mice; Mice, Inbred ICR; Nitriles; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein-Tyrosine Kinases; Pulmonary Embolism; Quinazolines; Receptors, Collagen; Signal Transduction; Thrombin; Thromboembolism; Thromboplastin | 2003 |